Abstract: An inverse emulsion copolymer composition comprises (A) an aqueous phase comprising a cross-linked hydrophilic polyelectrolyte copolymer (A?) obtained by the free radical copolymerisation of: (i) at least one anionic ethylenically unsaturated monomer bearing a negatively charged group and one polymerisable C?C double bond, or at least one cationic ethylenically unsaturated monomer bearing a positively charged group and one polymerisable C?C double bond, and (ii) at least one non-ionic ethylenically unsaturated cross-linking monomer bearing at least two polymerisable C?C double bonds, and (iii) optionally, one or more hydrophilic non-ionic ethylenically unsaturated monomers bearing one polymerisable C?C double bond, (B) an oil phase comprising a carrier oil (C), (D) (i) at least one water-in-oil emulsifying surfactant, and (D) (ii) at least one oil-in-water emulsifying surfactant; characterised in that the carrier oil component (C) of the oil phase comprises from 75% to 100%, by weight of the said carrier oil

Abstract: The present invention relates to a parenteral dosage form comprising a) a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, pH adjusting agent to provide a pH in the range of 3 to 5 and ethanol, and b) an infusion container filled with said aqueous solution.

Abstract: The present invention is predicated on the realisation that problems with the poor water solubility of arsenic trioxide and the extreme difficulty in dissolving arsenic trioxide in anything other than a very basic solution, could be overcome by forming a much more soluble diarsenic tetraoxide, including the compound NaHAs2O4, prior to its delivery to a patient. Pharmaceutical compositions with such compounds and their use in the treatment of cancers is disclosed.

Abstract: Disclosed are a pharmaceutical composition and a beauty-purposed pharmaceutical composition for prevention or treatment of neuromuscular disease, the composition including a combination of Erigeron annuus flower-based essential oil and Botox. Erigeron annuus flower-based essential oil inhibits t-SNARE protein and v-SNARE protein expression in neurons to inhibit the formation of SNARE protein complexes. Erigeron annuus flower-based essential oil inhibits the regeneration of t-SNARE protein and v-SNARE protein degraded by Botox to inhibit neurotransmitter release. Accordingly, an efficacy duration of Botox may be extended. Thus, Erigeron annuus flower-based essential oil may be usefully used in combination with Botox as Botox adjuvant for the prevention and treatment of neuromuscular disease or for beauty.

Abstract: A topical preparation containing vitamin K1 and a preparation method thereof are provided. The topical preparation includes the following components in weight percentage: 0.01-5% of vitamin K1, 0.1-25% of a transdermal enhancer and 70-99% of a matrix for the topical preparation. The transdermal enhancer is composed of urea, menthol and Eucalyptus oil in a mass ratio of (5-6):(2-3):(1-3). The topical preparation containing vitamin K1 can be used to treat moderate and severe skin toxicity caused by anti-tumor drugs related to epidermal growth factor receptor (EGFR), can effectively treat diseases such as acne-like rash, pruritus, red swelling, dry skin and mucositis caused by EGFR-related anti-tumor drugs, and can ensure the continued treatment with anti-EGFR targeting drugs. It can increase the possibility of vitamin K1 reaching focus sites in the dermal layer through the stratum corneum, and can rapidly alleviate moderate and severe skin diseases caused by EGFR-related anti-tumor drugs.

Abstract: To provide an acrylic silicone graft copolymer capable of effectively exerting a function in a composition for external application containing various oily components such as a natural oil, a hydrocarbon oil, ester oil and a silicone oil, and a composition for external application containing the acrylic silicone graft copolymer. A composition for external application including an acrylic silicone graft copolymer, which contains 2 to 25 mass % of a constitutional unit represented by formula (I), 55 to 85 mass % of a constitutional unit represented by formula (II) and 2 to 20 mass % of a constitutional unit represented by formula (III). wherein R1 is an alkyl group having 1 to 4 carbon atoms; R2 is an alkylene group having 2 to 10 carbon atoms; and n is an integer of 1 to 100.

Abstract: The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.

Abstract: One embodiment of the present invention relates to a composition comprising: (a) at least one first anionic surfactant selected from glutamic acid compounds and salts thereof; (b) at least one second anionic surfactant selected from alanine compounds and salts thereof, glycine compounds and salts thereof, and mixtures thereof; (c) at least one nonionic surfactant; and (d) at least one thickener. One embodiment according to the present invention is stable and can form foam with good quality.

Abstract: A drug delivery system (DDS) including a hydrophobic porous scaffold and a hydrogel having a hydrophilic polymer and one or more biologic drugs provides sustained zero-order release of the one or more biologic drugs. Also provided herein are methods of making and using a DDS including a hydrophobic porous scaffold and a hydrogel having a hydrophilic polymer and one or more biologic drugs.

Abstract: The present invention relates to a process for producing perfume- or flavor-containing polyurea microcapsules with improved deposition of encapsulated actives on targeted surfaces such as fiber, hair and skin, which can be used in home or personal care products, as well as to microcapsules obtainable by such a process and consumer products comprising these microcapsules.

Abstract: A cosmetic including an acryl silicone copolymer having a (meth)acrylic chain in the main chain and a structure containing at least a silicone macromonomer shown by the following general formula (1) as the monomer unit (the acryl silicone copolymer has a refractive index of 1.47 or more). A novel glossy cosmetic that is free from tautness or stiffness unlike previous silicone resin coatings, excellent in feeling of use, adherence, and flexibility, as well as good in effect for preventing color transfer.

Abstract: The disclosure provides personal care compositions that comprise a compound of formula (I) wherein n is an integer from 2 to 5, R1 is independently H or C1-C3 alkyl and R2 is an unsubstituted linear or branched C1-C6 alkyl and a cosmetically acceptable vehicle. In particular, the compound of formula (I) is diglycolamine acetamide The composition may be used to moisturise skin or hair.

Abstract: The disclosure provides personal care compositions that comprise a moisturizing agent of formula (I) wherein n is an integer from 2 to 5, R1 is independently H or C1-C3 alkyl and R2 is an unsubstituted linear or branched C1-C6 alkyl, at least one additional moisturizing agent and a cosmetically acceptable vehicle. In particular, the compound of formula (I) is diglycolamine acetamide. The compositions generally improve moisturization of skin and hair.

Abstract: The invention relates to the oral cosmetic use of a combination of active agents comprising at least taurine, a derivative thereof and/or an acceptable salt thereof and at least one grape extract, as cosmetic active agents for improving the quality of the nails. More particularly, the present invention relates to the oral cosmetic use of such a combination for improving the solidity of the nails and for reducing and/or preventing their splitting.

Abstract: A composition for an enteric hard capsule by taking advantage of conventionally unknown thermal gelation characteristics of a neutralized aqueous solution of an enteric polymer, so as to obtain an enteric capsule having sufficient water and acid resistances. More specifically, the composition has hypromellose acetate succinate having a molar substitution with an acetyl group per anhydroglucose unit of 0.6 to 0.8 and a ratio of the molar substitution with an acetyl group to a molar substitution with a succinyl group per anhydroglucose unit of 2.0 to 4.0, a neutralizer, and water method produces an enteric hard capsule having the steps of: immersing a core pin heated at 50 to 80° C. in the composition, taking the immersed core pin out of the composition, and drying a gel layer of the hypromellose acetate succinate formed on the taken-out core pin.

Abstract: Provided are a ceria nanocomposite including a ceria nanoparticle for treating subarachnoid hemorrhage, a method of preparing the same, and a pharmaceutical composition including the ceria nanocomposite. The ceria nanocomposite for treating subarachnoid hemorrhage disclosed herein includes a ceria nanoparticle and a surface modified layer disposed on a surface of the ceria nanoparticle, wherein the surface modified layer includes a polyethylene glycol residue.

Abstract: Embolic materials, suspensions, kits and related methods useful for embolization are disclosed. An embolic material can comprise a resorbable microsphere including cross-linked gelatin as its primary ingredient and having a substantially spherical shape with a diameter of about 50 micrometers to about 1,500 micrometers, inclusive. The microsphere can optionally include one or both of a marker or an active agent. The microsphere can be cross-linked, such as with glutaraldehyde or formaldehyde, which can affect the microsphere's in vivo degradation profile and ability to withstand a sterilization process at certain temperatures. In an embodiment, the microspheres can resorb during an in vivo time period of between about 24 hours and about 15 weeks, inclusive. An embolization suspension can include a plurality of resorbable microspheres and a liquid carrier, and the suspension can be disposed in a syringe, vial or other applicator for administration to a patient.

Abstract: The present invention relates to a skin depigmentation composition comprising (i) at least one thiophosphate derivative and (ii) acceptable carriers for topical, oral and/or parenteral administrations to human. The present invention further relates to the cosmetic and medical treatment uses thereof for reducing skin and/or hair pigmentation.

Abstract: Process for thickening a composition, through the use of a direct emulsion in water, which is alkali-swellable, of a polymer of the ASE or HASE type, which is both rich in acrylic acid and which has a certain quantity of AMPS. The use of such emulsions simultaneously allows there to be no obligation to use surfactants and organic solvents other than water, and allows the thickening phenomenon to be activated for pHs of less than 7: this latter characteristic is particularly advantageous for formulations intended to be used in contact with skin.